Sulfatide attenuates experimental Staphylococcus aureus sepsis through a CD1d-dependent pathway

Infection and Immunity

Volumn 81, Issue 4, 2013, Pages 1114-1120

  Kwiecinski, Jakub ^a   Rhost, Sara ^a   Löfbom, Linda ^a   Blomqvist, Maria ^a   Månsson, Jan Eric ^a   Cardell, Susanna L ^a   Jin, Tao ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD1D ANTIGEN; INTERLEUKIN 6; SULFATIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; INOCULATION; LETHALITY; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCAL BACTEREMIA; STAPHYLOCOCCUS AUREUS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84875551212     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01334-12     Document Type: Article

References (56)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. 2001. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 29:1303-1310.
2. Pfaller MA, Jones RN, Doern GV, Sader HS, Kugler KC, Beach ML. 1999. Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group. Diagn. Microbiol. Infect. Dis. 33:283-297.
3. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK. 2007. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298:1763-1771.
4. Gould IM, David MZ, Esposito S, Garau J, Lina G, Mazzei T, Peters G. 2012. New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. Int. J. Antimicrob. Agents 39:96-104.
5. Huttunen R, Aittoniemi J. 2011. New concepts in the pathogenesis, diagnosis and treatment of bacteremia and sepsis. J. Infect. 63:407-419.
6. Levi M, Ten Cate H. 1999. Disseminated intravascular coagulation. N. Engl. J. Med. 341:586-592.
7. Bendelac A, Savage PB, Teyton L. 2007. The biology of NKT cells. Annu. Rev. Immunol. 25:297-336.
8. Rhost S, Sedimbi S, Kadri N, Cardell SL. 2012. Immunomodulatory type II natural killer T lymphocytes in health and disease. Scand. J. Immunol. 76:246-255.
9. Behar SM, Cardell S. 2000. Diverse CD1d-restricted T cells: diverse phenotypes, and diverse functions. Semin. Immunol. 12:551-560.
10. Berzins SP, Smyth MJ, Baxter AG. 2011. Presumed guilty: natural killer T cell defects and human disease. Nat. Rev. Immunol. 11:131-142.
11. Skold M, Behar SM. 2003. Role of CD1d-restricted NKT cells in microbial immunity. Infect. Immun. 71:5447-5455.
12. Tupin E, Kinjo Y, Kronenberg M. 2007. The unique role of natural killer T cells in the response to microorganisms. Nat. Rev. Microbiol. 5:405-417.
13. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. 2004. NKT cells: what's in a name? Nat. Rev. Immunol. 4:231-237.
14. Blomqvist M, Rhost S, Teneberg S, Lofbom L, Osterbye T, Brigl M, Mansson JE, Cardell SL. 2009. Multiple tissue-specific isoforms of sulfatide activate CD1d-restricted type II NKT cells. Eur. J. Immunol. 39: 1726-1735.
15. Jahng A, Maricic I, Aguilera C, Cardell S, Halder RC, Kumar V. 2004. Prevention of autoimmunity by targeting a distinct, noninvariant CD1dreactive T cell population reactive to sulfatide. J. Exp. Med. 199:947-957.
16. Patel O, Pellicci DG, Gras S, Sandoval-Romero ML, Uldrich AP, Mallevaey T, Clarke AJ, Le Nours J, Theodossis A, Cardell SL, Gapin L, Godfrey DI, Rossjohn J. 2012. Recognition of CD1d-sulfatide mediated by a type II natural killer T cell antigen receptor. Nat. Immunol. 13:857-863.
17. Arrenberg P, Maricic I, Kumar V. 2011. Sulfatide-mediated activation of type II natural killer T cells prevents hepatic ischemic reperfusion injury in mice. Gastroenterology 140:646-655.
18. Halder RC, Aguilera C, Maricic I, Kumar V. 2007. Type II NKT cellmediated anergy induction in type I NKT cells prevents inflammatory liver disease. J. Clin. Investig. 117:2302-2312.
19. Leung B, Harris HW. 2011. NKT cells: the culprits of sepsis? J. Surg. Res. 167:87-95.
20. Dieli F, Sireci G, Russo D, Taniguchi M, Ivanyi J, Fernandez C, Troye-Blomberg M, De Leo G, Salerno A. 2000. Resistance of natural killer T cell-deficient mice to systemic Shwartzman reaction. J. Exp. Med. 192:1645-1652.
21. Hu CK, Venet F, Heffernan DS, Wang YL, Horner B, Huang X, Chung CS, Gregory SH, Ayala A. 2009. The role of hepatic invariant NKT cells in systemic/local inflammation and mortality during polymicrobial septic shock. J. Immunol. 182:2467-2475.
22. Ogasawara K, Takeda K, Hashimoto W, Satoh M, Okuyama R, Yanai N, Obinata M, Kumagai K, Takada H, Hiraide H, Seki S. 1998. Involvement of NK1+ T cells and their IFN-gamma; production in the generalized Shwartzman reaction. J. Immunol. 160:3522-3527.
23. Rhee RJ, Carlton S, Lomas JL, Lane C, Brossay L, Cioffi WG, Ayala A. 2003. Inhibition of CD1d activation suppresses septic mortality: a role for NK-T cells in septic immune dysfunction. J. Surg. Res. 115:74-81.
24. Sherwood ER, Lin CY, Tao W, Hartmann CA, Dujon JE, French AJ, Varma TK. 2003. Beta 2 microglobulin knockout mice are resistant tolethal intraabdominal sepsis. Am. J. Respir. Crit. Care Med. 167:1641-1649.
25. Skovbjerg S, Martner A, Hynsjo L, Hessle C, Olsen I, Dewhirst FE, Tham W, Wold AE. 2010. Gram-positive and gram-negative bacteria induce different patterns of cytokine production in human mononuclear cells irrespective of taxonomic relatedness. J. Interferon Cytokine Res. 30:23-32.
26. Lin KH, Liang JJ, Huang WI, Lin-Chu SY, Su CY, Lee YL, Jan JT, Lin YL, Cheng YS, Wong CH. 2010. In vivo protection provided by a synthetic new alpha-galactosyl ceramide analog against bacterial and viral infections in murine models. Antimicrob. Agents Chemother. 54:4129-4136.
27. Minagawa S, Ohyama C, Hatakeyama S, Tsuchiya N, Kato T, Habuchi T. 2005. Activation of natural killer T cells by alpha-galactosylceramide mediates clearance of bacteria in murine urinary tract infection. J. Urol. 173:2171-2174.
28. Tarkowski A, Collins LV, Gjertsson I, Hultgren OH, Jonsson IM, Sakiniene E, Verdrengh M. 2001. Model systems: modeling human staphylococcal arthritis and sepsis in the mouse. Trends Microbiol. 9:321-326.
29. Chen YH, Chiu NM, Mandal M, Wang N, Wang CR. 1997. Impaired NK1+ T cell development and early IL-4 production in CD1-deficient mice. Immunity 6:459-467.
30. Cui J, Shin T, Kawano T, Sato H, Kondo E, Toura I, Kaneko Y, Koseki H, Kanno M, Taniguchi M. 1997. Requirement for Valpha14 NKT cells in IL-12-mediated rejection of tumors. Science 278:1623-1626.
31. Rosengren B, Fredman P, Mansson JE, Svennerholm L. 1989. Lysosulfatide (galactosylsphingosine-3-O-sulfate) from metachromatic leukodystrophy and normal human brain. J. Neurochem. 52:1035-1041.
32. Bremell T, Lange S, Svensson L, Jennische E, Grondahl K, Carlsten H, Tarkowski A. 1990. Outbreak of spontaneous staphylococcal arthritis and osteitis in mice. Arthritis Rheum. 33:1739-1744.
33. Fei Y, Wang W, Kwiecinski J, Josefsson E, Pullerits R, Jonsson IM, Magnusson M, Jin T. 2011. The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice. J. Infect. Dis. 204:348-357.
34. Klak M, Anakkala N, Wang W, Lange S, Jonsson IM, Tarkowski A, Jin T. 2010. Tranexamic acid, an inhibitor of plasminogen activation, aggravates staphylococcal septic arthritis and sepsis. Scand. J. Infect. Dis. 42: 351-358.
35. Jin T, Bokarewa M, Zhu Y, Tarkowski A. 2008. Staphylokinase reduces plasmin formation by endogenous plasminogen activators. Eur. J. Haematol. 81:8-17.
36. Riedemann NC, Guo RF, Ward PA. 2003. Novel strategies for the treatment of sepsis. Nat. Med. 9:517-524.
37. Etogo AO, Nunez J, Lin CY, Toliver-Kinsky TE, Sherwood ER. 2008. NK but not CD1-restricted NKT cells facilitate systemic inflammation during polymicrobial intra-abdominal sepsis. J. Immunol. 180:6334-6345.
38. Squadrito F, Bagnato G, Altavilla D, Ferlito M, Campo GM, Squadrito G, Urna G, Sardella A, Arlotta M, Minutoli L, Quartarone C, Saitta A, Caputi AP. 1999. Effect of sulfatide on acute lung injury during endotoxemia in rats. Life Sci. 65:2541-2552.
39. Higashi H, Suzuki Y, Mukaida N, Takahashi N, Miyamoto D, Matsushima K. 1997. Intervention in endotoxin shock by sulfatide (I3SO3- GalCer) with a concomitant reduction in tumor necrosis factor alpha production. Infect. Immun. 65:1223-1227.
40. Hultgren O, Eugster HP, Sedgwick JD, Korner H, Tarkowski A. 1998. TNF/lymphotoxin-alpha double-mutant mice resist septic arthritis but display increased mortality in response to Staphylococcus aureus. J. Immunol. 161:5937-5942.
41. Stenzel W, Soltek S, Miletic H, Hermann MM, Korner H, Sedgwick JD, Schluter D, Deckert M. 2005. An essential role for tumor necrosis factor in the formation of experimental murine Staphylococcus aureus-induced brain abscess and clearance. J. Neuropathol. Exp. Neurol. 64:27-36.
42. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, Zinkernagel R, Bluethmann H, Kohler G. 1994. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342.
43. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, Shatin D, Saag KG. 2007. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. Arthritis Rheum. 56:1125-1133.
44. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, Vinh DC. 2003. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect. Dis. 3:148-155.
45. Hyrich KL, Silman AJ, Watson KD, Symmons DP. 2004. Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety. Ann. Rheum. Dis. 63:1538-1543.
46. Kling A, Mjorndal T, Rantapaa-Dahlqvist S. 2004. Sepsis as a possible adverse drug reaction in patients with rheumatoid arthritis treated with TNFalpha antagonists. J. Clin. Rheumatol. 10:119-122.
47. Ogata A, Hirano T, Hishitani Y, Tanaka T. 2012. Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin. Med. Insights Arthritis Musculoskelet. Disord. 5:27-42.
48. Aruffo A, Kolanus W, Walz G, Fredman P, Seed B. 1991. CD62/Pselectin recognition of myeloid and tumor cell sulfatides. Cell 67:35-44.
49. Bai L, Picard D, Anderson B, Chaudhary V, Luoma A, Jabri B, Adams EJ, Savage PB, Bendelac A. 2012. The majority of CD1d-sulfatide-specific T cells in human blood use a semiinvariant Vdelta1 TCR. Eur. J. Immunol. 42:2505-2510.
50. Ambrosino E, Terabe M, Halder RC, Peng J, Takaku S, Miyake S, Yamamura T, Kumar V, Berzofsky JA. 2007. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J. Immunol. 179:5126-5136.
51. ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJ. 1997. Cytokines: triggers of clinical thrombotic disease. Thromb. Haemost. 78: 415-419.
52. van der Poll T, Buller HR, ten Cate H, Wortel CH, Bauer KA, van Deventer SJ, Hack CE, Sauerwein HP, Rosenberg RD, ten Cate JW. 1990. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N. Engl. J. Med. 322:1622-1627.
53. Bertozzi P, Astedt B, Zenzius L, Lynch K, LeMaire F, Zapol W, Chapman HA, Jr. 1990. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N. Engl. J. Med. 322:890-897.
54. Idell S, James KK, Levin EG, Schwartz BS, Manchanda N, Maunder RJ, Martin TR, McLarty J, Fair DS. 1989. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J. Clin. Investig. 84:695-705.
55. Querol-Ribelles JM, Tenias JM, Grau E, Querol-Borras JM, Climent JL, Gomez E, Martinez I. 2004. Plasma d-dimer levels correlate with outcomes in patients with community-acquired pneumonia. Chest 126: 1087-1092.
56. Raaphorst J, Johan Groeneveld AB, Bossink AW, Erik Hack C. 2001. Early inhibition of activated fibrinolysis predicts microbial infection, shock and mortality in febrile medical patients. Thromb. Haemost. 86: 543-549.